The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers
- PMID: 1451729
- DOI: 10.1007/BF02220625
The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers
Abstract
We have studied the effects of quinidine on ECG intervals and on the pharmacokinetics of flecainide and its two metabolites in 6 healthy men in an open randomized crossover study. Flecainide acetate (150 mg) was given as a constant rate i.v. infusion over 30 min. Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h). This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1). The excretion of the metabolites of flecainide over 48 h was significantly reduced. These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1). The effects of flecainide on ECG intervals were not altered by quinidine. Thus, quinidine tends to shift extensive metabolizer status for flecainide towards poor metabolizer status and may also alter its renal excretion.
Similar articles
-
Altered flecainide disposition in healthy volunteers taking quinine.Eur J Clin Pharmacol. 1990;38(3):269-73. doi: 10.1007/BF00315029. Eur J Clin Pharmacol. 1990. PMID: 2111245
-
Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.Br J Clin Pharmacol. 1992 Mar;33(3):275-80. doi: 10.1111/j.1365-2125.1992.tb04035.x. Br J Clin Pharmacol. 1992. PMID: 1576047 Free PMC article.
-
Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone.Clin Pharmacol Ther. 1994 Mar;55(3):256-69. doi: 10.1038/clpt.1994.26. Clin Pharmacol Ther. 1994. PMID: 8143391
-
Clinical pharmacokinetics of quinidine.Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003. Clin Pharmacokinet. 1980. PMID: 6988137 Review.
-
[Determination of correlations between the main pharmacokinetic parameters and physiopathological factors of flecainide in the elderly].Therapie. 1991 May-Jun;46(3):179-82. Therapie. 1991. PMID: 1724326 Review. French.
Cited by
-
Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein.AAPS J. 2017 Mar;19(2):409-420. doi: 10.1208/s12248-016-0023-y. Epub 2016 Dec 27. AAPS J. 2017. PMID: 28028729 Free PMC article. Review.
-
Antiarrhythmic agents: drug interactions of clinical significance.Drug Saf. 2000 Dec;23(6):509-32. doi: 10.2165/00002018-200023060-00003. Drug Saf. 2000. PMID: 11144659 Review.
-
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.Br J Clin Pharmacol. 2008 Nov;66(5):660-6. doi: 10.1111/j.1365-2125.2008.03267.x. Epub 2008 Jul 24. Br J Clin Pharmacol. 2008. PMID: 18754843 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous